Orthocell Limited

CHIA:OCC Stock Report

Market Cap: AU$274.0m

Orthocell Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Paul Anderson

Chief executive officer

AU$621.6k

Total compensation

CEO salary percentage70.8%
CEO tenure18.8yrs
CEO ownership1.6%
Management average tenure1.9yrs
Board average tenure6.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Paul Anderson's remuneration changed compared to Orthocell's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024AU$622kAU$440k

-AU$7m

Mar 31 2024n/an/a

-AU$7m

Dec 31 2023n/an/a

-AU$7m

Sep 30 2023n/an/a

-AU$7m

Jun 30 2023AU$651kAU$420k

-AU$6m

Mar 31 2023n/an/a

-AU$7m

Dec 31 2022n/an/a

-AU$9m

Sep 30 2022n/an/a

-AU$9m

Jun 30 2022AU$531kAU$380k

-AU$9m

Mar 31 2022n/an/a

-AU$9m

Dec 31 2021n/an/a

-AU$9m

Sep 30 2021n/an/a

-AU$9m

Jun 30 2021AU$1mAU$375k

-AU$9m

Mar 31 2021n/an/a

-AU$9m

Dec 31 2020n/an/a

-AU$8m

Sep 30 2020n/an/a

-AU$7m

Jun 30 2020AU$578kAU$370k

-AU$6m

Mar 31 2020n/an/a

-AU$6m

Dec 31 2019n/an/a

-AU$7m

Sep 30 2019n/an/a

-AU$6m

Jun 30 2019AU$582kAU$365k

-AU$6m

Mar 31 2019n/an/a

-AU$6m

Dec 31 2018n/an/a

-AU$6m

Sep 30 2018n/an/a

-AU$6m

Jun 30 2018AU$597kAU$365k

-AU$6m

Compensation vs Market: Paul's total compensation ($USD394.30K) is below average for companies of similar size in the Australian market ($USD703.61K).

Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.

CEO

Paul Anderson (58 yo)

18.8yrs

Tenure

AU$621,574

Compensation

Mr. Paul Frederick Anderson serves as Chief Executive Officer of Orthocell Limited. Mr. Anderson has been Managing Director and Executive Director of Orthocell Limited since March 21, 2006. Mr. Anderson ha...

Leadership Team

NamePositionTenureCompensationOwnership
Paul Anderson
CEO, MD & Executive Directorno dataAU$621.57k1.55%
A$ 4.3m
Nicole Telford
Chief Financial Officerno datano data1.48%
A$ 4.0m
Alex McHenry
Chief Operating Officer5.9yrsno datano data
Ming Hao Zheng
Chief Scientific Officer and Member of Medical & Scientific Advisory Boardno datano data1.42%
A$ 3.9m
Tony Macintyre
Chief Technical Operations Officer1.9yrsno datano data
Peter Webse
Company Secretary1.8yrsno datano data

1.9yrs

Average Tenure

Experienced Management: OCC's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Paul Anderson
CEO, MD & Executive Director18.8yrsAU$621.57k1.55%
A$ 4.3m
Ming Hao Zheng
Chief Scientific Officer and Member of Medical & Scientific Advisory Boardno datano data1.42%
A$ 3.9m
Fiona Wood
Independent Non-Executive Director1.1yrsAU$448.66k0.0068%
A$ 18.5k
Samuel Asculai
Chairman of Medical & Scientific Advisory Boardno datano datano data
Ray Crowe
Member of Medical & Scientific Advisory Boardno datano datano data
Gregory Janes
Member of Medical & Scientific Advisory Boardno datano datano data
David Wood
Member of Medical & Scientific Advisory Boardno datano datano data
Alan Wang
Member of Medical & Scientific Advisory Boardno datano datano data
John Van Der Wielen
Independent Non-Executive Chairman1.5yrsAU$150.00k0.21%
A$ 563.0k
Rocky Tuan
Member of Medical & Scientific Advisory Board8.8yrsno datano data
Massimo Simion
Member of Medical & Scientific Advisory Board6.8yrsno datano data
Giuseppe Luongo
Member of Medical & Scientific Advisory Board6.8yrsno datano data

6.8yrs

Average Tenure

Experienced Board: OCC's board of directors are considered experienced (6.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/17 02:49
End of Day Share Price 2024/12/17 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Orthocell Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tara SperanzaBell Potter